WallStSmart

Belite Bio Inc ADR (BLTE)vsJohnson & Johnson (JNJ)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).

BLTE

Avoid

20

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 3/9Altman Z: 45.99

JNJ

Buy

57

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 2.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BLTE.

JNJSignificantly Overvalued (-83.0%)

Margin of Safety

-83.0%

Fair Value

$144.12

Current Price

$275.19

$131.07 premium

UndervaluedFair: $144.12Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLTE1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
45.9910/10

Safe zone — low bankruptcy risk

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$615.87B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
25.1%8/10

Strong operational efficiency at 25.1%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

Areas to Watch

BLTE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

JNJ4 concerns · Avg: 2.8/10
P/E RatioValuation
38.8x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.822/10

Expensive relative to growth rate

EPS GrowthGrowth
-96.0%2/10

Earnings declined 96.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : BLTE

The strongest argument for BLTE centers on Altman Z-Score.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.

Bear Case : BLTE

The primary concerns for BLTE are Revenue Growth, EPS Growth, Profit Margin.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

BLTE profiles as a value stock while JNJ is a mature play — different risk/reward profiles.

JNJ carries more volatility with a beta of 0.21 — expect wider price swings.

JNJ is growing revenue faster at 5.9% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

JNJ scores higher overall (57/100 vs 20/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Belite Bio Inc ADR

HEALTHCARE · BIOTECHNOLOGY · USA

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?